News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel

News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel

Sign In

New Clinical Laboratory Test Exposes Cancer Cells with Ultra Violet Light: Improves Accuracy of Current Cancer Assays, Say Researchers

New technology accurately distinguishes between cancerous cells and healthy cells. Will it give pathologists a “universal” assay for cancer diagnosis?

In England, a university team has developed a new technology for detecting circulating cancer cells in blood. Their method uses ultraviolet light and the results are so promising that efforts are now underway to develop this method into a clinical laboratory test.

That is why pathologists and medical laboratory professionals may soon have a new tool in their arsenal: one that significantly aids physicians and medical laboratories in the diagnosis of cancer. (more…)

At the University of Michigan, Research Study Indicates how Composition of Gut Microbiome May Serve as Complementary, Noninvasive Screening Tool for Colon Cancer

If validated by additional research, microbiologists, pathologists, and medical laboratory professionals might soon find analysis of the human microbiome to be a useful marker in screening for colon cancer

Microbiologists may play a greater role in the early detection of colorectal cancer, if the findings of a research study at the University of Michigan (UMich) are confirmed with additional clinical studies.

Combining gut microbiome analysis with traditional risk factors for colorectal cancer—such as body mass index (BMI), age, and race—significantly improved the ability of pathologists to distinguish healthy people from those with precancerous or cancerous lesions, wrote researchers from the UMich in a scholarly paper published in the November 2014 issue in Cancer Prevention Research.

Research findings indicate that gut microbiomes may be a major factor in development of colorectal cancer. However, more research is required to determine if this microbial community has the potential to be clinically useful as screening tool for early-stage disease. (more…)

Cigna to Preauthorize Genetic Tests

Clinical laboratories and pathology groups serving Cigna beneficiaries can expect to see new requirements for genetic tests used to diagnose breast cancer, colon cancer and long QT syndrome

Effective this week, Cigna (NYSE: CI) in Bloomfield, Connecticut, is implementing a new program that requires genetic counseling and pre-authorization for certain genetic tests. This is an important development and clinical laboratory executives can expect to see other health insurers take similar steps.

Cigna wants to control costs and improve the appropriateness of ordering expensive genetic tests. It will start with tests for three conditions and may require counseling for other types of genetic tests if this program is successful. Industry observers expect other health insurers will follow Cigna’s example and also require genetic counseling for a compelling reason: all insurers recognize that more than 50% of all genetic tests may be ordered inappropriately, experts say.

(more…)

Cheap, Fast, Accurate Home Colon Cancer Test Joins Growing List of Diagnostic Tests Shifting from Medical Laboratories to Homes

Steady progress is happening in consumer self-test kits as new diagnostic technology supports at-home kits that produce results with accuracy approaching 90%

Because screening for colon cancer represents a potentially huge number of medical laboratory tests each year, many biotech companies are racing to develop reliable test kits that patients can use at home. But to be successful, the test kit must be cheap, easy for a consumer to use, and produce clinically useful results.

Home Test Promises Same Accuracy as Clinical Laboratory Test

That’s the goal of Mode Diagnostics, Ltd., a Scottish company that is poised to sell a consumer device that can detect signs of colon cancer at home in three minutes at an accuracy rate of 98%. Mode’s new device is an example of how innovative diagnostic technology is driving the market for fast, accurate consumer self-test kits—and pushing these tests out of the central clinical laboratory and into the home. (more…)

Group Health Cooperative Study Uses EHRs and Stepped Interventions to Double Rate of Colorectal Cancer Screenings

Pathologists and clinical laboratory managers may find new opportunities to increase testing volumes as patients’electronic health records yield clinically relevant data

Sophisticated use of electronic health records (EHRs), automated reminder systems, and telephone follow-up can double cancer-screening compliance by consumers. That could mean an increase in testing volumes for clinical laboratories serving clinics using this approach.

Researchers at the Group Health Research Institute (GHRI) used electronic health records to identify Group Health Cooperative (GHC) patients who weren’t screened regularly for cancer of the colon and rectum.

Because of how EHRs were used to step-up patient compliance for cancer screening, the study findings may be useful for pathologists and clinical laboratory managers. Over the years, many medical laboratories have furnished referring physicians a list of their patients who are due for screening tests, such as for cervical cancer. (more…)

;